Yellow Vine

Coscinium usitatum contains berberine as its primary alkaloid, exerting antimicrobial effects through bacterial membrane disruption and antihypertensive effects via modulation of calcium channels and nitric oxide pathways. In rat models, methanol stem extracts and their fractionated alkaloid-enriched fractions reduced mean arterial blood pressure by up to 60.60% and heart rate by 48.50%, outcomes comparable to the reference drug atenolol at 52.80% MABP reduction.

Origin & History

Coscinium usitatum Lour. (closely related to and often synonymized with Coscinium fenestratum) is native to the tropical forests of Southeast Asia and South Asia, distributed across Vietnam, Thailand, Sri Lanka, India, and Myanmar, typically growing as a large woody climber in humid lowland and montane forest ecosystems. The plant favors well-drained, fertile soils under forest canopy at elevations up to approximately 1,000 meters. Its stems and roots are the primary harvested parts; due to unsustainable wild harvesting driven by high demand in traditional medicine markets, the species is now classified as endangered, and cultivation efforts remain limited.

Historical & Cultural Context

Coscinium usitatum and the closely related Coscinium fenestratum have been integral to Ayurvedic medicine in South Asia, where the plant is colloquially called 'Tree Turmeric' due to the vivid yellow color of its stem wood imparted by berberine, and has been traditionally prescribed for jaundice, fever, urinary tract infections, gonorrhea, and as a bitter digestive tonic. In Vietnamese and Thai ethnomedicine, the dried stem is a valued component of multi-herb antipyretic and antimicrobial formulas, often combined with other berberine-containing plants such as Coptis chinensis or Berberis species to enhance anti-infective potency. The plant's yellow berberine-rich stem wood has also been historically used as a natural dye for cloth and as a topical antiseptic paste applied to skin infections and wounds across the Indian subcontinent and Indochina. Sustained overharvesting from wild populations, driven by persistent demand in traditional medicine markets across Asia, has led to the species' endangered status under IUCN-equivalent regional assessments, prompting conservation alerts in Sri Lanka and India by the early 2000s.

Health Benefits

- **Antimicrobial Activity**: Berberine-rich stem extracts demonstrate minimum inhibitory concentrations (MIC) of 47.39 µg/mL against Neisseria gonorrhoeae, consistent with berberine's documented mechanism of disrupting bacterial membrane integrity and inhibiting DNA gyrase, supporting its traditional use in treating gonorrhea and wound infections.
- **Antihypertensive Effects**: Methanol extract fractions (particularly fraction-E, enriched in alkaloids and flavonoids) reduced mean arterial blood pressure by 60.60%, heart rate by 48.50%, and force of cardiac contraction by 58.40% in rat models, likely through calcium channel antagonism and nitric oxide-mediated vasorelaxation attributed to naringin and berberine.
- **Antioxidant Protection**: Methanolic leaf extracts exhibit DPPH radical scavenging with an IC50 of 182.48 µg/mL, and ABTS•+ inhibition ranging from 32.54–44.21% at 50–150 µg/mL, driven by the electron-donating hydroxyl groups of flavonoids (quercetin, naringin) and phenolic acids quantified at 14.54–19.21 mg gallic acid equivalents/g extract.
- **Enzymatic Antioxidant Upregulation**: Alcoholic stem extracts have been shown in animal models to upregulate endogenous antioxidant enzymes including catalase and superoxide dismutase, suggesting a secondary layer of oxidative stress protection beyond direct free-radical scavenging by phenolic compounds.
- **Anti-infective Traditional Applications**: Widely employed in Vietnamese and Thai ethnomedicine for reducing fever and managing bacterial infections, consistent with berberine's broad-spectrum activity against gram-positive and gram-negative bacteria and its documented anti-inflammatory actions via NF-κB pathway suppression.
- **Phytosterol and Ecdysteroid Content**: GC-MS analysis confirmed the presence of 20-hydroxyecdysone (20E; m/z 481 [M+H]+, C27H44O7) in leaf and stem extracts, a compound associated with anabolic, adaptogenic, and anti-inflammatory properties in preclinical research, though its contribution to the plant's overall pharmacological profile requires further characterization.
- **Reducing Power and Metal Chelation**: Stem and leaf extracts demonstrate concentration-dependent ferric reducing antioxidant power (FRAP), with absorbance increasing from 0.610 to 1.060 across 50–250 µg/mL, indicating potential metal-chelating and reducing activity useful in countering oxidative stress-mediated chronic disease.

How It Works

Berberine, the dominant alkaloid in Coscinium usitatum stems and leaves (yielding up to 215 mg per extraction fraction via chloroform-methanol HPLC-guided isolation), exerts antimicrobial effects by intercalating into bacterial DNA, inhibiting topoisomerase II (DNA gyrase), and disrupting cell membrane integrity, thereby achieving MIC values as low as 47.39 µg/mL against Neisseria gonorrhoeae. The antihypertensive mechanism involves vasorelaxation mediated by flavonoids such as naringin and quercetin, which modulate L-type calcium channel activity to reduce vascular smooth muscle contractility and may stimulate endothelial nitric oxide synthase (eNOS) to increase NO bioavailability, an effect amplified by alkaloid co-presence in fraction-E extracts. Antioxidant activity operates through two parallel pathways: direct radical quenching by phenolic hydroxyl groups (quantified flavonoids at 42 mg quercetin equivalents/g methanolic extract; total phenolics 14.54–19.21 mg/g) and indirect upregulation of catalase and superoxide dismutase in hepatic and renal tissues, as demonstrated in oral alcoholic-extract animal studies. The ecdysteroid 20-hydroxyecdysone may additionally interact with ecdysone receptors or mammalian estrogen receptor-β to modulate anabolic and anti-inflammatory gene expression, though this pathway remains uncharacterized in the context of this species.

Scientific Research

The entirety of available evidence for Coscinium usitatum derives from in vitro phytochemical assays, GC-MS and HPLC profiling studies, and animal (rat) pharmacological experiments; no peer-reviewed human clinical trials have been conducted or identified to date, representing a significant gap in the translational evidence base. Antihypertensive efficacy was demonstrated in rat models comparing graded oral doses of methanol extract fractions against atenolol as a positive control, showing up to 60.60% reduction in MABP and 58.40% reduction in force of cardiac contraction, though sample sizes and formal statistical parameters (confidence intervals, exact p-values) were not reported in available sources. Antimicrobial data against Neisseria gonorrhoeae (MIC 47.39 µg/mL) and antioxidant profiling (DPPH IC50 182.48 µg/mL) were generated exclusively via standardized in vitro assay protocols, which, while reproducible and informative for mechanistic insight, cannot be directly extrapolated to human therapeutic doses or outcomes. Overall, the evidence base is best categorized as preclinical and preliminary; while results are biologically plausible and consistent with the broader berberine pharmacology literature, regulatory-quality dose-response data, pharmacokinetic studies in humans, and randomized controlled trials are entirely absent.

Clinical Summary

No human clinical trials have been conducted for Coscinium usitatum in isolation; all pharmacological outcome data originate from animal models and in vitro experimental systems. The most robust preclinical outcome is a rat-model antihypertensive study in which methanol extract fraction-E produced a 60.60% reduction in mean arterial blood pressure and a 48.50% reduction in heart rate, numerically exceeding the reference drug atenolol's 52.80% MABP reduction, though the absence of reported sample sizes, variance measures, or formal inferential statistics substantially limits confidence in these figures. Antimicrobial and antioxidant findings are drawn from standardized biochemical assays (DPPH, ABTS, FRAP, MIC broth dilution) that provide mechanistic plausibility but no clinical effect-size data. Given the endangered conservation status of the plant and absence of human pharmacokinetic or safety data, the translation of these preclinical findings into clinical recommendations is not currently justified without substantially expanded research infrastructure.

Nutritional Profile

Coscinium usitatum is not consumed as a food and has no conventional macronutrient profile; its pharmacological relevance derives entirely from secondary metabolite content. Primary phytochemicals include berberine alkaloid (dominant; 15.20–19.21 mg berberine hydrochloride equivalents/g in alkaloid-enriched extracts; 215 mg isolated from stem fractions per extraction run), total flavonoids (42 mg quercetin equivalents/g methanolic leaf extract), and total phenolics (14.54–19.21 mg gallic acid equivalents/g across aqueous and methanol Soxhlet extracts). Additional phytochemical classes confirmed qualitatively in methanolic extracts include saponins, triterpenoids, steroids, tannins, glycosides, and resins. GC-MS analysis identified 30 volatile/semi-volatile compounds, with bis(2,4,6-triisopropylphenyl)phosphinicazide as the most prominent at 6.70% peak area, and confirmed 20-hydroxyecdysone (C27H44O7, MW ~480 Da) by mass spectrometry. Berberine bioavailability from oral plant extracts is expected to be low (estimated 1–5% based on general berberine pharmacokinetic literature), with intestinal P-glycoprotein efflux and first-pass metabolism as primary limiting factors, though species-specific human bioavailability data do not exist.

Preparation & Dosage

- **Methanolic Stem/Leaf Extract (Research Standard)**: Soxhlet extraction with methanol yields approximately 15.8% w/w extract, used at graded doses in animal antihypertensive studies; human equivalent dose not established.
- **Aqueous Soxhlet Extract**: Yields 14.54–19.21 mg alkaloid equivalents/g dry material; traditionally prepared as decoctions of dried stem wood for fever and infection management in Vietnamese and Thai folk medicine.
- **Chloroform-Methanol Fractional Extract**: Used for berberine isolation (yielding 215 mg from stem, 200 mg from leaf fractions); not a consumer-available form but the basis for standardized berberine-content preparations.
- **Dichloromethane/Ethyl Acetate/Butanol Partitioned Fractions**: Employed in antihypertensive animal research to isolate active alkaloid-flavonoid fractions; fraction-E demonstrated the highest cardiovascular activity.
- **Traditional Stem Decoction**: Dried stem slices boiled in water, consumed orally; preparation method used in Ayurvedic and Southeast Asian ethnomedicine for managing fever, gonorrhea, and hypertension, with no standardized dose documented in clinical literature.
- **Standardization**: No commercial standardized extracts of Coscinium usitatum are widely available; berberine content of approximately 15.20–19.21 mg/g in alkaloid-rich extracts provides a provisional phytochemical benchmark.
- **Dosage Note**: No safe or effective human dose has been established; general berberine pharmacology literature suggests 500–1500 mg/day for berberine hydrochloride in clinical trials for other indications, but direct application to this species is speculative without species-specific bioavailability data.

Synergy & Pairings

Berberine in Coscinium usitatum extracts is pharmacologically complementary with piperine (from Piper nigrum), which inhibits P-glycoprotein efflux and CYP3A4-mediated first-pass metabolism of berberine, potentially increasing oral bioavailability from the estimated 1–5% baseline to therapeutically relevant plasma concentrations, a synergy well-documented in the broader berberine literature. Co-administration with quercetin or naringin (both present endogenously within the plant's own flavonoid fraction) may produce additive antihypertensive and antioxidant effects through complementary calcium channel modulation and radical-scavenging pathways, as suggested by the enhanced MABP reduction observed with the flavonoid-alkaloid co-enriched fraction-E versus crude extract alone. In traditional Vietnamese multi-herb formulas, Coscinium usitatum stem is often paired with anti-inflammatory herbs containing curcuminoids or other berberine-containing plants (such as Mahonia or Berberis species), a practice consistent with known additive or synergistic antimicrobial activity across berberine-rich botanicals.

Safety & Interactions

No formal human safety studies, dose-escalation trials, or adverse event reports have been published for Coscinium usitatum; animal pharmacological studies at effective antihypertensive doses reported no overt signs of acute toxicity, but the absence of structured toxicological evaluation (LD50, sub-chronic toxicity, genotoxicity) means a comprehensive safety profile cannot be established. Based on its high berberine content, potential drug interactions include additive hypotensive effects when co-administered with antihypertensive agents (beta-blockers, calcium channel blockers, ACE inhibitors), additive hypoglycemic effects with metformin or insulin, and inhibition of CYP3A4 and CYP2D6 enzymes by berberine, which could elevate plasma concentrations of co-administered substrates such as cyclosporine, statins, or certain antiarrhythmics. Berberine is contraindicated in pregnancy due to documented uterotonic effects and potential neonatal jaundice risk through displacement of bilirubin from albumin binding sites, and the same caution applies to Coscinium usitatum extracts by pharmacological analogy. Individuals with hypotension, cardiac conduction disorders, or hepatic impairment should exercise particular caution; given the endangered status of the plant and the complete absence of clinical safety data in humans, unsupervised supplementation is not advisable.